254 related articles for article (PubMed ID: 10811121)
1. Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1.
Carr-Brendel V; Markovic D; Ferrer K; Smith M; Taylor-Papadimitriou J; Cohen EP
Cancer Res; 2000 May; 60(9):2435-43. PubMed ID: 10811121
[TBL] [Abstract][Full Text] [Related]
2. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha.
Musiani P; Allione A; Modica A; Lollini PL; Giovarelli M; Cavallo F; Belardelli F; Forni G; Modesti A
Lab Invest; 1996 Jan; 74(1):146-57. PubMed ID: 8569177
[TBL] [Abstract][Full Text] [Related]
3. Treatment of breast cancer with fibroblasts transfected with DNA from breast cancer cells.
de Zoeten E; Carr-Brendel V; Markovic D; Taylor-Papadimitriou J; Cohen EP
J Immunol; 1999 Jun; 162(11):6934-41. PubMed ID: 10352316
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral injection of IL-secreting syngeneic/allogeneic fibroblasts transfected with DNA from breast cancer cells prolongs the survival of mice with intracerebral breast cancer.
Lichtor T; Glick RP; Lin H; O-Sullivan I; Cohen EP
Cancer Gene Ther; 2005 Aug; 12(8):708-14. PubMed ID: 15803143
[TBL] [Abstract][Full Text] [Related]
5. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
6. Nature and potential of the reactive response to mouse mammary adenocarcinoma cells engineered with interleukin-2, interleukin-4 or interferon-gamma genes.
Musiani P; Modesti A; Brunetti M; Modica A; Vitullo P; Gulino A; Bosco MC; Colombo MP; Nanni P; Cavallo F
Nat Immun; 1994; 13(2-3):93-101. PubMed ID: 8173240
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing.
Eguchi J; Hiroishi K; Ishii S; Mitamura K
Cancer Immunol Immunother; 2003 Jun; 52(6):378-86. PubMed ID: 12739068
[TBL] [Abstract][Full Text] [Related]
8. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells.
Gastl G; Finstad CL; Guarini A; Bosl G; Gilboa E; Bander NH; Gansbacher B
Cancer Res; 1992 Nov; 52(22):6229-36. PubMed ID: 1423266
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP
Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045
[TBL] [Abstract][Full Text] [Related]
10. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine.
Chung MA; Luo Y; O'Donnell M; Rodriguez C; Heber W; Sharma S; Chang HR
Cancer Res; 2003 Mar; 63(6):1280-7. PubMed ID: 12649188
[TBL] [Abstract][Full Text] [Related]
11. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model.
Emtage PC; Wan Y; Bramson JL; Graham FL; Gauldie J
J Immunol; 1998 Mar; 160(5):2531-8. PubMed ID: 9498799
[TBL] [Abstract][Full Text] [Related]
12. Cooperative effects of Mycobacterium tuberculosis Ag38 gene transduction and interleukin 12 in vaccination against spontaneous tumor development in proto-neu transgenic mice.
Sfondrini L; Rodolfo M; Singh M; Colombo MP; Colnaghi MI; Ménard S; Balsari A
Cancer Res; 2000 Jul; 60(14):3777-81. PubMed ID: 10919650
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
[TBL] [Abstract][Full Text] [Related]
14. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
15. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice.
Comes A; Di Carlo E; Musiani P; Rosso O; Meazza R; Chiodoni C; Colombo MP; Ferrini S
Eur J Immunol; 2002 Jul; 32(7):1914-23. PubMed ID: 12115611
[TBL] [Abstract][Full Text] [Related]
16. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants.
Allione A; Consalvo M; Nanni P; Lollini PL; Cavallo F; Giovarelli M; Forni M; Gulino A; Colombo MP; Dellabona P
Cancer Res; 1994 Dec; 54(23):6022-6. PubMed ID: 7954438
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma.
Dorsey R; Kundu N; Yang Q; Tannenbaum CS; Sun H; Hamilton TA; Fulton AM
Cancer Res; 2002 May; 62(9):2606-10. PubMed ID: 11980656
[TBL] [Abstract][Full Text] [Related]
18. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
Abdel-Wahab Z; Dar M; Osanto S; Fong T; Vervaert CE; Hester D; Jolly D; Seigler HF
Cancer Gene Ther; 1997; 4(1):33-41. PubMed ID: 9012449
[TBL] [Abstract][Full Text] [Related]
19. Immunity to growth factor receptor-bound protein 10, a signal transduction molecule, inhibits the growth of breast cancer in mice.
O-Sullivan I; Chopra A; Carr J; Kim TS; Cohen EP
Cancer Res; 2008 Apr; 68(7):2463-70. PubMed ID: 18381455
[TBL] [Abstract][Full Text] [Related]
20. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.
De Giovanni C; Nicoletti G; Landuzzi L; Astolfi A; Croci S; Comes A; Ferrini S; Meazza R; Iezzi M; Di Carlo E; Musiani P; Cavallo F; Nanni P; Lollini PL
Cancer Res; 2004 Jun; 64(11):4001-9. PubMed ID: 15173014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
